Publications
normDesign: Bayesian sample size for non-inferiority randomized trials with normal data (SAS).., 2016.
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma." Cancer Discov 7, no. 10 (2017): 1116-1135.
"Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma." Cancer Discov 7, no. 10 (2017): 1116-1135.
"Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma." Cancer Discov 7, no. 10 (2017): 1116-1135.
"Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma." Cancer Discov 7, no. 10 (2017): 1116-1135.
"Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups." Lung Cancer 90, no. 2 (2015): 281-7.
"Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials." Oncologist 22, no. 2 (2017): 189-198.
"The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies." J Biopharm Stat 25, no. 1 (2015): 66-88.
"UNC-Utah NA-MIC framework for DTI fiber tract analysis." Front Neuroinform 7 (2014): 51.
"Tximeta: Reference sequence checksums for provenance identification in RNA-seq." PLoS Comput Biol 16, no. 2 (2020): e1007664.
"Tximeta: Reference sequence checksums for provenance identification in RNA-seq." PLoS Comput Biol 16, no. 2 (2020): e1007664.
"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
"Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases." J Clin Oncol 34, no. 9 (2016): 945-52.
"Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer." J Thorac Oncol 14, no. 2 (2019): 298-303.
"Ten-year experience with extended criteria cardiac transplantation." Circ Heart Fail 6, no. 6 (2013): 1230-8.
"SynthEx: a synthetic-normal-based DNA sequencing tool for copy number alteration detection and tumor heterogeneity profiling." Genome Biol 18, no. 1 (2017): 66.
"SynthEx: a synthetic-normal-based DNA sequencing tool for copy number alteration detection and tumor heterogeneity profiling." Genome Biol 18, no. 1 (2017): 66.
"Swimming downstream: statistical analysis of differential transcript usage following Salmon quantification." F1000Res 7 (2018): 952.
"Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation." Ann Am Thorac Soc 14, no. 2 (2017): 172-181.
"Studying gene and gene-environment effects of uncommon and common variants on continuous traits: a marker-set approach using gene-trait similarity regression." Am J Hum Genet 89, no. 2 (2011): 277-88.
"Statistical Considerations for Subgroup Analyses." J Thorac Oncol 16, no. 3 (2021): 375-380.
"Statistical aspect of translational and correlative studies in clinical trials." Chin Clin Oncol 5, no. 1 (2016): 11.
"Static and Dynamic DNA Loops form AP-1-Bound Activation Hubs during Macrophage Development." Mol Cell 67, no. 6 (2017): 1037-1048.e6.
"Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy." Nat Commun 11, no. 1 (2020): 6410.
"Semiparametric regression models and sensitivity analysis of longitudinal data with nonrandom dropouts." Stat Neerl 64, no. 2 (2010): 133-156.
"Semiparametric estimation of structural failure time models in continuous-time processes." Biometrika 107, no. 1 (2020): 123-136.
"Secondary outcome analysis for data from an outcome-dependent sampling design." Stat Med 37, no. 15 (2018): 2321-2337.
"Seamless Phase IIa/IIb and enhanced dose-finding adaptive design." J Biopharm Stat 26, no. 5 (2016): 912-23.
"Sample size considerations of prediction-validation methods in high-dimensional data for survival outcomes." Genet Epidemiol 37, no. 3 (2013): 276-82.
"Robust Multicategory Support Vector Machines using Difference Convex Algorithm." Math Program 169, no. 1 (2018): 277-305.
"Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies." J Natl Cancer Inst 109, no. 8 (2017).
"Regression analysis for secondary response variable in a case-cohort study." Biometrics 74, no. 3 (2018): 1014-1022.
"Reexamining Dis/Similarity-Based Tests for Rare-Variant Association with Case-Control Samples." Genetics 209, no. 1 (2018): 105-113.
"Receiver operating characteristic curves and confidence bands for support vector machines." Biometrics 77, no. 4 (2021): 1422-1430.
"Random Effects Model for Multiple Pathway Analysis with Applications to Type II Diabetes Microarray Data." Stat Biosci 7, no. 2 (2015): 167-186.
"Radiomics analysis using stability selection supervised component analysis for right-censored survival data." Comput Biol Med 124 (2020): 103959.
"Racial Differences in Diffusion of Intensity-Modulated Radiation Therapy for Localized Prostate Cancer." Am J Mens Health 10, no. 5 (2016): 399-407.
"Quantifying the average of the time-varying hazard ratio via a class of transformations." Lifetime Data Anal 21, no. 2 (2015): 259-79.
"Quantifying center of pressure variability in chondrodystrophoid dogs." Vet J 226 (2017): 26-31.
"Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer." Clin Cancer Res 26, no. 1 (2020): 82-92.
"Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer." Clin Cancer Res 26, no. 1 (2020): 82-92.
"Proper Use of Allele-Specific Expression Improves Statistical Power for -eQTL Mapping with RNA-Seq Data." J Am Stat Assoc 110, no. 511 (2015): 962-974.
"Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer." Lung Cancer 141 (2020): 14-20.
"A practical Bayesian adaptive design incorporating data from historical controls." Stat Med 37, no. 27 (2018): 4054-4070.
"Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies." J Clin Oncol 35, no. 25 (2017): 2885-2892.
"Pathway-based identification of SNPs predictive of survival." Eur J Hum Genet 19, no. 6 (2011): 704-9.
"Optimal treatment allocations in space and time for on-line control of an emerging infectious disease." J R Stat Soc Ser C Appl Stat 67, no. 4 (2018): 743-770.
"Observation weights unlock bulk RNA-seq tools for zero inflation and single-cell applications." Genome Biol 19, no. 1 (2018): 24.
"A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events." Pharm Stat 14, no. 4 (2015): 273-83.
"Nine-year change in statistical design, profile, and success rates of Phase II oncology trials." J Biopharm Stat 26, no. 1 (2016): 141-9.
"Nine-year change in statistical design, profile, and success rates of Phase II oncology trials." J Biopharm Stat 26, no. 1 (2016): 141-9.
"Multivariate longitudinal shape analysis of human lateral ventricles during the first twenty-four months of life." PLoS One 9, no. 9 (2014): e108306.
"Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint." Stat Med 30, no. 13 (2011): 1502-18.
"A multiple imputation strategy for sequential multiple assignment randomized trials." Stat Med 33, no. 24 (2014): 4202-14.
"The Long Noncoding RNA Promotes Sarcoma Metastasis by Regulating RNA Splicing Pathways." Mol Cancer Res 18, no. 10 (2020): 1534-1544.
"Latent class model characterization of neighborhood socioeconomic status." Cancer Causes Control 27, no. 3 (2016): 445-52.
"A junction coverage compatibility score to quantify the reliability of transcript abundance estimates and annotation catalogs." Life Sci Alliance 2, no. 1 (2019).
"Intergenerational response to the endocrine disruptor vinclozolin is influenced by maternal genotype and crossing scheme." Reprod Toxicol 78 (2018): 9-19.
"Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial." Biostatistics 12, no. 2 (2011): 258-69.
"Incorporating Functional Information in Tests of Excess De Novo Mutational Load." Am J Hum Genet 97, no. 2 (2015): 272-83.
"I-Boost: an integrative boosting approach for predicting survival time with multiple genomics platforms." Genome Biol 20, no. 1 (2019): 52.
"I-Boost: an integrative boosting approach for predicting survival time with multiple genomics platforms." Genome Biol 20, no. 1 (2019): 52.
"High-Dimensional Inference for Personalized Treatment Decision." Electron J Stat 12, no. 1 (2018): 2074-2089.
"A global sensitivity test for evaluating statistical hypotheses with nonidentifiable models." Biometrics 66, no. 2 (2010): 558-66.
"A global logrank test for adaptive treatment strategies based on observational studies." Stat Med 33, no. 5 (2014): 760-71.
"Global copy number profiling of cancer genomes." Bioinformatics 32, no. 6 (2016): 926-8.
"Global copy number profiling of cancer genomes." Bioinformatics 32, no. 6 (2016): 926-8.
"Genetic analyses of diverse populations improves discovery for complex traits." Nature 570, no. 7762 (2019): 514-518.
"Genetic analyses of diverse populations improves discovery for complex traits." Nature 570, no. 7762 (2019): 514-518.
"Genetic analyses of diverse populations improves discovery for complex traits." Nature 570, no. 7762 (2019): 514-518.
"Genetic analyses of diverse populations improves discovery for complex traits." Nature 570, no. 7762 (2019): 514-518.
"Genetic analyses of diverse populations improves discovery for complex traits." Nature 570, no. 7762 (2019): 514-518.
"Genetic analyses of diverse populations improves discovery for complex traits." Nature 570, no. 7762 (2019): 514-518.
"Gene selection using iterative feature elimination random forests for survival outcomes." IEEE/ACM Trans Comput Biol Bioinform 9, no. 5 (2012): 1422-31.
"A framework for transcriptome-wide association studies in breast cancer in diverse study populations." Genome Biol 21, no. 1 (2020): 42.
"Factor selection and structural identification in the interaction ANOVA model." Biometrics 69, no. 1 (2013): 70-9.
"Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012." J Clin Oncol 34, no. 33 (2016): 3992-3999.
"Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial." JAMA Oncol 5, no. 10 (2019): 1448-1455.
"Dynamic treatment regimes: technical challenges and applications." Electron J Stat 8, no. 1 (2014): 1225-1272.
"Discussion of Laber et al. "Optimal treatment allocations in space and time for on-line control of an emerging infectious disease"." J R Stat Soc Ser C Appl Stat 67, no. 4 (2018): 779-780.
"Differential losses to follow-up that are outcome-dependent can vitiate a clinical trial: Simulation results." J Biopharm Stat 28, no. 4 (2018): 633-644.
"Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas." Cancer Causes Control 30, no. 1 (2019): 31-39.
"Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical Trials." JAMA Netw Open 3, no. 10 (2020): e2014661.
"Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical Trials." JAMA Netw Open 3, no. 10 (2020): e2014661.
"